Dec 18, 2024 8:00am EST SCYNEXIS Initiates Dosing in Phase 1 Trial of SCY-247, a Second-Generation Fungerp Candidate for Invasive Fungal Infections
Nov 6, 2024 4:30pm EST SCYNEXIS Reports Third Quarter 2024 Financial Results and Provides Corporate Update